MedTrace Logo

Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia

NCT00124891 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2022-05-03

No results posted yet for this study

Summary

To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).

Conditions

Interventions

DRUG

Double-blind investigational anti-arrhythmic

DRUG

GAP-486

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-01
Primary Completion
2006-11-01
Completion
2006-11-01

Countries

  • United States
  • Brazil
  • Canada
  • Croatia
  • Denmark
  • Hungary
  • India
  • Italy
  • Mexico
  • Poland
  • Romania
  • Russia
  • Serbia
  • Sweden
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00124891 on ClinicalTrials.gov